⚡ Quick Answer
Xafinact to doustna safinamide (50 mg or 100 mg) tablet — a selective monoamine oxidase type B (MAO-B) inhibitor stosowany w leczeniu Parkinson disease. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Safinamide adds a unique glutamate-modulating effect on top of MAO-B inhibition — it blocks voltage-dependent sodium channels and reduces stimulated glutamate release in the basal ganglia. Licensed only as adjunct to levodopa, not as monotherapy. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Ważne: avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of zespół serotoninowy.
📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.
Dlaczego warto zamawiać z MedsBase
Nasze leki generyczne pochodzą od producentów posiadających certyfikat WHO-GMP i są wysyłane na cały świat w dyskretnym, zwykłym opakowaniu — bez nazwy leku na zewnątrz przesyłki. Płatności kartami są kierowane przez regulowanego procesora (opis wyciągu zawiera nazwę regulowanego procesora płatności — nigdy “MedsBase” ani żadnej nazwy leku). Akceptujemy również kryptowaluty i przelewy bankowe SEPA. Każde zamówienie jest objęte naszą Reshipment Assurance Policy.
What Is Xafinact?
Xafinact is an oral tablet containing safinamide 50 mg or 100 mg. safinamide is a selective monoamine oxidase type B (MAO-B) inhibitor originally introduced as Xadago. Xafinact is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.
Safinamide is the newest MAO-B inhibitor (approved by the EMA in 2015 and FDA in 2017). Its dual mechanism — reversible MAO-B inhibition plus sodium-channel and glutamate modulation — was designed specifically to address levodopa-induced dyskinesia and wearing-off in fluctuating Parkinson patients. Unlike selegiline and rasagiline, it is licensed only as an adjunct to levodopa, never as monotherapy.
How Does Xafinact (safinamide) Work?
Safinamide works through two parallel mechanisms. The dopaminergic action — reversible, highly selective MAO-B inhibition — raises brain dopamine levels and lengthens the effect of each levodopa dose. The non-dopaminergic action — voltage-dependent sodium-channel blockade and reduced stimulated glutamate release — dampens the abnormal glutamate signalling in the basal ganglia that contributes to levodopa-induced dyskinesia. The combination explains why safinamide reduces dyskinesia where most other dopaminergic agents would worsen it.
Comparing the MAO-B Inhibitors
The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:
| Cecha | Selegiline | Rasagiline | Safinamide |
|---|---|---|---|
| Typical dose | 5–10 mg/day | 0.5–1 mg/day | 50–100 mg/day |
| Active metabolites | Amphetamine + methamphetamine | Aminoindan (non-amphetamine) | No active stimulant metabolite |
| Glutamate effect | Nie | Nie | Yes — sodium-channel/glutamate-release modulation |
| Wskazanie | Monotherapy or adjunct | Monotherapy or adjunct | Adjunct only — for fluctuating PD on levodopa |
| Insomnia risk | Higher (amphetamine metabolites) | Low | Low |
Who Is Xafinact For?
Xafinact is appropriate for adults with mid- or late-stage Parkinson disease on stable levodopa therapy who are experiencing motor fluctuations (end-of-dose wearing-off). It is otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. licensed for early monotherapy — rasagiline or selegiline are the appropriate MAO-B options for that. Patients with severe hepatic impairment, retinal disease (especially albinism, retinitis pigmentosa, retinal degeneration, severe diabetic retinopathy or uveitis) should not use safinamide.
Dosing and Administration
The standard regimen is 50 mg once daily for 2 weeks as a starting dose, then increased to 100 mg raz na dobę if tolerated. There is no benefit to higher doses; above 100 mg/day MAO-B selectivity is lost. Take in the morning with or without food. May be combined with any standard levodopa regimen; the levodopa dose may need a small reduction (10–30%) if dyskinesia worsens.
| Faza | Dawka |
|---|---|
| Weeks 1–2 | 50 mg once daily, morning |
| Maintenance (if 50 mg insufficient) | 100 mg raz na dobę |
| Ciężka niewydolność wątroby | Unikać |
Częste działania niepożądane
Dyskinesia (a paradoxical early effect — safinamide initially amplifies levodopa effect, so dyskinesia can increase in the first weeks before settling), nausea, insomnia, postural hypotension, fall risk. Less common: visual hallucinations, anxiety, weight loss. Retinal toxicity has been a concern in animal studies but has not been seen at any meaningful frequency in humans — nonetheless, eye examination before starting and periodically is recommended for patients with pre-existing retinal disease.
Drug and Food Interactions
- Antidepressants — SSRIs, SNRIs, TCAs: avoid. If a serotonergic antidepressant is essential, mirtazapine or bupropion are sometimes used cautiously under specialist supervision.
- Opioids — pethidine, tramadol, methadone: contraindicated. Morphine, codeine, oxycodone are safer alternatives if analgesia is required.
- Sympathomimetics — pseudoephedrine, phenylephrine, ephedrine: risk of hypertensive crisis. Avoid OTC decongestants.
- Other MAO inhibitors — phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue: contraindicated.
- CYP1A2 inducers/inhibitors — safinamide is metabolised mainly by non-CYP pathways (amidase enzymes); few clinically important interactions.
- Lewodopa — intentional combination: start at the lower MAO-B dose and watch for dyskinesia (a sign that levodopa effect has been amplified). Levodopa dose may need a 10–30% reduction.
Najczęściej zadawane pytania
Can I take Xafinact instead of levodopa?
No — unlike selegiline and rasagiline, safinamide is licensed only as an adjunct to levodopa. It has not been studied as monotherapy and would be unlikely to provide adequate symptom control alone.
How quickly will I feel an effect?
MAO-B inhibitors work gradually. Most patients notice a smoother “on” period and reduced “off” time within 2–4 weeks. The full benefit on motor fluctuations is usually clear by 4–8 weeks.
Will I have to follow a low-tyramine diet?
At normal prescribed doses (selegiline ≤ 10 mg/day, rasagiline 1 mg/day, safinamide ≤ 100 mg/day), no special diet is required. Above those doses, MAO-B selectivity is lost and tyramine restriction becomes important.
Does Xafinact slow down Parkinson disease itself?
A neuroprotective or disease-modifying effect of MAO-B inhibitors has been studied (e.g. the DATATOP and ADAGIO trials with selegiline and rasagiline). Results are suggestive but not definitive. The drugs are prescribed primarily for symptom control, not as guaranteed disease-modifying therapy.
Co zrobić, jeśli pominię dawkę?
Weź pominiętą dawkę tak szybko, jak to możliwe that day. If it is already evening or close to bedtime, skip it — selegiline and rasagiline can both cause insomnia, and a late dose can disrupt sleep. Never double-dose. Resume normal schedule the next day.
Can I drink alcohol with Xafinact?
Moderate alcohol is not strictly forbidden, but heavy drinking and red-wine binges can interact with residual MAO inhibition and increase blood-pressure variability. Many Parkinson patients also have postural hypotension on dopaminergic therapy — alcohol worsens this. Limit to 1 standard drink occasionally.
Can I drive while taking Xafinact?
Most patients tolerate Xafinact without driving impairment. However, dopaminergic therapy as a whole can cause sudden-onset sleep (sleep attacks), particularly when Xafinact is added to a dopamine agonist or levodopa. Until you know how you respond, avoid driving long distances or operating heavy machinery.
Is Xafinact safe in older adults?
Yes — safinamide is widely used in elderly Parkinson patients. Watch for postural hypotension (rise from sitting slowly), confusion, hallucinations, and impulse-control changes. Lower starting doses may be appropriate.
Can Xafinact be stopped abruptly?
No. Sudden withdrawal of any dopaminergic agent in a Parkinson patient can precipitate a neuroleptic-malignant-like syndrome with rigidity, fever and altered consciousness. If discontinuation is needed, taper over 1–2 weeks under medical supervision.
Will Xafinact cause weight loss or weight gain?
Neither markedly. Some patients on selegiline lose a small amount of weight (the amphetamine-like metabolites can suppress appetite slightly). Rasagiline and safinamide are weight-neutral.
How does MedsBase ship Xafinact?
Worldwide shipping in discreet packaging from a WHO-GMP certified manufacturer. Tablets are shipped in original sealed blister packs. Track your order from your MedsBase account.
Przechowywanie
Store at room temperature (15–30°C / 59–86°F), protected from heat, moisture and direct light. Keep in the original container with the lid tightly closed. Keep out of reach of children. Do not use beyond the expiry date printed on the packaging.
Medical Disclaimer
This information is provided for educational purposes only and is not a substitute for the advice of a qualified clinician. Parkinson disease and parkinsonian syndromes require individualised neurology care. Discuss all medications, supplements and pre-existing conditions with your doctor before starting, changing or stopping treatment. Do not abruptly discontinue dopaminergic therapy — sudden withdrawal can precipitate a neuroleptic malignant-like syndrome.
Powiązane alternatywy
Inne produkty w Choroby przewlekłe które klienci również przeglądają:
































Opinie
Nie ma jeszcze opinii